Symbols / AARD Stock $5.39 +0.37% Aardvark Therapeutics, Inc.
AARD (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Ratings
Current target
$5.39
Low
$6.00
High
$45.00
Mean
$16.90
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-24 | reit | BTIG | Buy → Buy | $9 |
| 2026-03-02 | main | Oppenheimer | Outperform → Outperform | $21 |
| 2026-03-02 | main | BTIG | Buy → Buy | $9 |
| 2026-03-02 | down | Morgan Stanley | Overweight → Equal-Weight | $7 |
| 2026-03-02 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2026-03-02 | down | Stifel | Buy → Hold | $6 |
| 2026-03-02 | down | RBC Capital | Outperform → Sector Perform | $6 |
| 2026-02-10 | reit | BTIG | Buy → Buy | $26 |
| 2026-02-09 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-12-23 | init | Oppenheimer | — → Outperform | $35 |
| 2025-12-12 | init | William Blair | — → Outperform | — |
| 2025-11-14 | main | RBC Capital | Outperform → Outperform | $18 |
| 2025-11-07 | init | BTIG | — → Buy | $26 |
| 2025-10-01 | init | Jones Trading | — → Buy | $33 |
| 2025-09-29 | init | Stifel | — → Buy | $24 |
| 2025-09-23 | reit | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-08-28 | main | B of A Securities | Buy → Buy | $25 |
| 2025-08-14 | main | RBC Capital | Outperform → Outperform | $19 |
| 2025-06-30 | init | HC Wainwright & Co. | — → Buy | $40 |
| 2025-05-15 | main | RBC Capital | Outperform → Outperform | $20 |
- Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat Sun, 26 Apr 2026 06
- AARD Stock Price and Chart — NASDAQ:AARD - TradingView Fri, 17 Apr 2026 15
- $AARD stock is down 14% today. Here's what we see in our data. - Quiver Quantitative Fri, 20 Mar 2026 07
- Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman - Morningstar Wed, 22 Apr 2026 18
- Aardvark Therapeutics (NASDAQ: AARD) launches $150M at-the-market stock program - Stock Titan Mon, 23 Mar 2026 07
- AARD (Aardvark) posts narrower than expected Q4 2025 loss, shares rise more than four percent today. - Real Trader Insights - UBND thành phố Hải Phòng Wed, 22 Apr 2026 21
- AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial - Stocktwits Mon, 02 Mar 2026 08
- Aardvark (AARD) Stock Mega Cap Focus (Trend Weakens) 2026-04-16 - Expert Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh hu, 16 Apr 2026 16
- A Look At Aardvark Therapeutics (AARD) Valuation After The Voluntary Pause Of Its Phase 3 HERO Trial - Yahoo Finance Wed, 04 Mar 2026 08
- Aardvark Therapeutics stock plunges after trial pause - Investing.com Mon, 02 Mar 2026 08
- $AARD stock is down 54% today. Here's what we see in our data. - Quiver Quantitative Mon, 02 Mar 2026 08
- [EFFECT] Aardvark Therapeutics, Inc. SEC Filing - Stock Titan Sun, 05 Apr 2026 07
- Aardvark Therapeutics (AARD) Is Down 61.4% After Pausing Phase 3 HERO Trial Over Cardiac Safety Questions - Yahoo Finance ue, 03 Mar 2026 08
- Aardvark halts obesity and PWS studies after reversible heart findings - Stock Titan Mon, 23 Mar 2026 07
- New Analyst Forecast: $AARD Given $26.0 Price Target | AARD Stock News - Quiver Quantitative Fri, 07 Nov 2025 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
62.73
+176.71%
|
22.67
+240.72%
|
6.65
-38.82%
|
10.87
|
| Research And Development |
|
48.94
+181.84%
|
17.36
+287.57%
|
4.48
-37.53%
|
7.17
|
| Selling General And Administration |
|
13.79
+159.92%
|
5.30
+144.13%
|
2.17
-19.58%
|
2.70
|
| General And Administrative Expense |
|
13.79
+159.92%
|
5.30
+144.13%
|
2.17
-19.58%
|
2.70
|
| Other Gand A |
|
13.79
+159.92%
|
5.30
+144.13%
|
2.17
-19.58%
|
2.70
|
| Total Expenses |
|
62.73
+176.71%
|
22.67
+240.72%
|
6.65
-38.82%
|
10.87
|
| Operating Income |
|
-62.73
-176.71%
|
-22.67
-240.72%
|
-6.65
+38.82%
|
-10.87
|
| Total Operating Income As Reported |
|
-62.73
-175.29%
|
-22.79
-207.28%
|
-7.42
+34.74%
|
-11.36
|
| EBITDA |
|
-62.69
-176.75%
|
-22.65
-240.48%
|
-6.65
+38.19%
|
-10.76
|
| Normalized EBITDA |
|
-62.68
-180.87%
|
-22.32
-377.39%
|
-4.67
+41.22%
|
-7.95
|
| Reconciled Depreciation |
|
0.04
+125.00%
|
0.02
|
0.00
-100.00%
|
0.11
|
| EBIT |
|
-62.73
-176.71%
|
-22.67
-240.72%
|
-6.65
+38.82%
|
-10.87
|
| Total Unusual Items |
|
-0.01
+98.50%
|
-0.33
+83.11%
|
-1.98
+29.61%
|
-2.81
|
| Total Unusual Items Excluding Goodwill |
|
-0.01
+98.50%
|
-0.33
+83.11%
|
-1.98
+29.61%
|
-2.81
|
| Special Income Charges |
|
0.00
+100.00%
|
-0.12
+84.65%
|
-0.76
-55.83%
|
-0.49
|
| Other Special Charges |
|
—
|
—
|
—
|
1.00
|
| Write Off |
|
0.00
-100.00%
|
0.12
-84.65%
|
0.76
+55.83%
|
0.49
|
| Net Income |
|
-57.59
-179.73%
|
-20.59
-185.63%
|
-7.21
+46.86%
|
-13.56
|
| Pretax Income |
|
-57.59
-179.73%
|
-20.59
-185.63%
|
-7.21
+46.86%
|
-13.56
|
| Net Non Operating Interest Income Expense |
|
5.14
+112.88%
|
2.41
+69.64%
|
1.42
+1085.83%
|
0.12
|
| Net Interest Income |
|
5.14
+112.88%
|
2.41
+69.64%
|
1.42
+1085.83%
|
0.12
|
| Interest Income Non Operating |
|
5.14
+112.88%
|
2.41
+69.64%
|
1.42
+1085.83%
|
0.12
|
| Interest Income |
|
5.14
+112.88%
|
2.41
+69.64%
|
1.42
+1085.83%
|
0.12
|
| Other Income Expense |
|
-0.01
+98.50%
|
-0.33
+83.11%
|
-1.98
+29.61%
|
-2.81
|
| Gain On Sale Of Security |
|
-0.01
+97.70%
|
-0.22
+82.15%
|
-1.22
+47.61%
|
-2.32
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-57.59
-179.73%
|
-20.59
-185.63%
|
-7.21
+46.86%
|
-13.56
|
| Net Income From Continuing Operation Net Minority Interest |
|
-57.59
-179.73%
|
-20.59
-185.63%
|
-7.21
+46.86%
|
-13.56
|
| Net Income From Continuing And Discontinued Operation |
|
-57.59
-179.73%
|
-20.59
-185.63%
|
-7.21
+46.86%
|
-13.56
|
| Net Income Continuous Operations |
|
-57.59
-179.73%
|
-20.59
-185.63%
|
-7.21
+46.86%
|
-13.56
|
| Normalized Income |
|
-57.59
-184.32%
|
-20.25
-287.27%
|
-5.23
+51.37%
|
-10.75
|
| Net Income Common Stockholders |
|
-57.59
-179.73%
|
-20.59
-185.63%
|
-7.21
+46.86%
|
-13.56
|
| Diluted EPS |
|
-2.93
-204.33%
|
-0.96
-72.43%
|
-0.56
+59.94%
|
-1.39
|
| Basic EPS |
|
-2.93
-204.33%
|
-0.96
-72.43%
|
-0.56
+59.94%
|
-1.39
|
| Basic Average Shares |
|
19.62
-8.23%
|
21.38
+65.65%
|
12.91
+32.64%
|
9.73
|
| Diluted Average Shares |
|
19.62
-8.23%
|
21.38
+65.65%
|
12.91
+32.64%
|
9.73
|
| Diluted NI Availto Com Stockholders |
|
-57.59
-179.73%
|
-20.59
-185.63%
|
-7.21
+46.86%
|
-13.56
|
| Provision For Doubtful Accounts |
|
—
|
0.12
|
0.00
-100.00%
|
1.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
117.18
+51.19%
|
77.51
+635.64%
|
10.54
-37.12%
|
16.76
|
| Current Assets |
|
111.89
+50.92%
|
74.14
+615.06%
|
10.37
-37.13%
|
16.49
|
| Cash Cash Equivalents And Short Term Investments |
|
110.03
+49.37%
|
73.66
+637.44%
|
9.99
-37.98%
|
16.11
|
| Cash And Cash Equivalents |
|
47.05
-23.67%
|
61.64
+533.19%
|
9.73
-37.43%
|
15.56
|
| Other Short Term Investments |
|
62.98
+423.84%
|
12.02
+4633.07%
|
0.25
-53.48%
|
0.55
|
| Prepaid Assets |
|
—
|
0.31
+24.60%
|
0.25
-20.25%
|
0.32
|
| Other Current Assets |
|
1.86
+292.19%
|
0.47
+273.23%
|
0.13
+81.43%
|
0.07
|
| Total Non Current Assets |
|
5.29
+57.12%
|
3.37
+1905.95%
|
0.17
-36.84%
|
0.27
|
| Net PPE |
|
0.35
-51.70%
|
0.73
+374.19%
|
0.15
-38.49%
|
0.25
|
| Gross PPE |
|
0.35
-51.70%
|
0.73
+374.19%
|
0.15
-38.49%
|
0.25
|
| Other Properties |
|
0.35
-51.70%
|
0.73
+374.19%
|
0.15
-38.49%
|
0.25
|
| Other Non Current Assets |
|
4.94
+87.48%
|
2.63
+20169.23%
|
0.01
-7.14%
|
0.01
|
| Total Liabilities Net Minority Interest |
|
10.55
-92.02%
|
132.15
+191.48%
|
45.34
+1.47%
|
44.68
|
| Current Liabilities |
|
10.55
+114.09%
|
4.93
+256.51%
|
1.38
+132.27%
|
0.59
|
| Payables And Accrued Expenses |
|
7.19
+94.80%
|
3.69
+201.47%
|
1.23
+177.15%
|
0.44
|
| Payables |
|
2.07
-9.83%
|
2.30
+122.03%
|
1.03
+299.61%
|
0.26
|
| Accounts Payable |
|
2.07
-9.83%
|
2.30
+122.03%
|
1.03
+299.61%
|
0.26
|
| Current Accrued Expenses |
|
5.12
+267.17%
|
1.40
+634.21%
|
0.19
+3.83%
|
0.18
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.91
+1194.67%
|
0.23
+400.00%
|
0.04
-15.09%
|
0.05
|
| Current Debt And Capital Lease Obligation |
|
0.44
+30.47%
|
0.34
+201.79%
|
0.11
+12.00%
|
0.10
|
| Current Capital Lease Obligation |
|
0.44
+30.47%
|
0.34
+201.79%
|
0.11
+12.00%
|
0.10
|
| Current Deferred Liabilities |
|
0.00
-100.00%
|
0.67
|
0.00
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-100.00%
|
127.22
+189.43%
|
43.96
-0.29%
|
44.09
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
-100.00%
|
0.44
+782.00%
|
0.05
-69.14%
|
0.16
|
| Long Term Capital Lease Obligation |
|
0.00
-100.00%
|
0.44
+782.00%
|
0.05
-69.14%
|
0.16
|
| Other Non Current Liabilities |
|
—
|
0.03
+1200.00%
|
0.00
-89.47%
|
0.02
|
| Preferred Securities Outside Stock Equity |
|
0.00
-100.00%
|
126.76
+188.71%
|
43.90
+0.00%
|
43.90
|
| Stockholders Equity |
|
106.63
+295.14%
|
-54.64
-57.01%
|
-34.80
-24.64%
|
-27.92
|
| Common Stock Equity |
|
106.63
+295.14%
|
-54.64
-57.01%
|
-34.80
-24.64%
|
-27.92
|
| Capital Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
—
|
—
|
| Share Issued |
|
21.82
+0.59%
|
21.69
+1.42%
|
21.38
+0.00%
|
21.38
|
| Ordinary Shares Number |
|
21.82
+0.59%
|
21.69
+1.42%
|
21.38
+0.00%
|
21.38
|
| Additional Paid In Capital |
|
222.47
+5938.82%
|
3.68
+25.43%
|
2.94
+12.62%
|
2.61
|
| Retained Earnings |
|
-115.92
-98.74%
|
-58.33
-54.55%
|
-37.74
-23.61%
|
-30.53
|
| Gains Losses Not Affecting Retained Earnings |
|
0.08
|
0.00
|
—
|
—
|
| Other Equity Adjustments |
|
0.08
|
—
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
106.63
+295.14%
|
-54.64
-57.01%
|
-34.80
-24.64%
|
-27.92
|
| Total Capitalization |
|
106.63
+295.14%
|
-54.64
-57.01%
|
-34.80
-24.64%
|
-27.92
|
| Working Capital |
|
101.34
+46.42%
|
69.21
+670.20%
|
8.99
-43.47%
|
15.90
|
| Invested Capital |
|
106.63
+295.14%
|
-54.64
-57.01%
|
-34.80
-24.64%
|
-27.92
|
| Total Debt |
|
0.44
-43.39%
|
0.78
+380.86%
|
0.16
-38.17%
|
0.26
|
| Capital Lease Obligations |
|
0.44
-43.39%
|
0.78
+380.86%
|
0.16
-38.17%
|
0.26
|
| Net Tangible Assets |
|
106.63
+295.14%
|
-54.64
-57.01%
|
-34.80
-24.64%
|
-27.92
|
| Tangible Book Value |
|
106.63
+295.14%
|
-54.64
-57.01%
|
-34.80
-24.64%
|
-27.92
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-54.17
-199.51%
|
-18.09
-210.56%
|
-5.82
+44.76%
|
-10.54
|
| Cash Flow From Continuing Operating Activities |
|
-54.17
-199.51%
|
-18.09
-210.56%
|
-5.82
+44.76%
|
-10.54
|
| Net Income From Continuing Operations |
|
-57.59
-179.73%
|
-20.59
-185.63%
|
-7.21
+46.86%
|
-13.56
|
| Depreciation Amortization Depletion |
|
0.04
+125.00%
|
0.02
|
0.00
-100.00%
|
0.11
|
| Depreciation |
|
0.04
+125.00%
|
0.02
|
0.00
-100.00%
|
0.11
|
| Depreciation And Amortization |
|
0.04
+125.00%
|
0.02
|
0.00
-100.00%
|
0.11
|
| Other Non Cash Items |
|
0.38
+61.70%
|
0.23
+142.27%
|
0.10
-90.30%
|
1.00
|
| Stock Based Compensation |
|
3.95
+799.32%
|
0.44
+40.26%
|
0.31
-24.03%
|
0.41
|
| Provisionand Write Offof Assets |
|
0.00
-100.00%
|
0.12
-84.65%
|
0.76
+55.83%
|
0.49
|
| Operating Gains Losses |
|
—
|
—
|
-0.92
|
—
|
| Gain Loss On Investment Securities |
|
—
|
—
|
-0.92
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
0.01
-97.70%
|
0.22
-82.15%
|
1.22
-47.61%
|
2.32
|
| Change In Working Capital |
|
0.36
-77.37%
|
1.57
+2041.98%
|
-0.08
+93.82%
|
-1.31
|
| Change In Prepaid Assets |
|
-5.96
-1346.60%
|
-0.41
+45.43%
|
-0.76
-85.96%
|
-0.41
|
| Change In Payables And Accrued Expense |
|
6.65
+204.81%
|
2.18
+182.04%
|
0.77
+196.27%
|
-0.80
|
| Change In Accrued Expense |
|
6.42
+363.18%
|
1.39
+69350.00%
|
-0.00
+99.76%
|
-0.83
|
| Change In Payable |
|
0.24
-70.05%
|
0.80
+2.84%
|
0.78
+2403.23%
|
0.03
|
| Change In Account Payable |
|
0.24
-70.05%
|
0.80
+2.84%
|
0.78
+2403.23%
|
0.03
|
| Change In Other Current Liabilities |
|
-0.34
-70.71%
|
-0.20
-98.00%
|
-0.10
+0.99%
|
-0.10
|
| Investing Cash Flow |
|
-49.67
-313.96%
|
-12.00
|
0.00
+100.00%
|
-1.00
|
| Cash Flow From Continuing Investing Activities |
|
-49.67
-313.96%
|
-12.00
|
0.00
+100.00%
|
-1.00
|
| Net PPE Purchase And Sale |
|
-0.10
+12.84%
|
-0.11
|
0.00
|
—
|
| Purchase Of PPE |
|
-0.10
+12.84%
|
-0.11
|
0.00
|
—
|
| Capital Expenditure |
|
-0.10
+12.84%
|
-0.11
|
—
|
—
|
| Net Investment Purchase And Sale |
|
-49.57
-316.96%
|
-11.89
|
0.00
|
—
|
| Purchase Of Investment |
|
-129.60
-990.07%
|
-11.89
|
0.00
|
—
|
| Sale Of Investment |
|
80.03
|
0.00
|
—
|
—
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
-1.00
|
| Financing Cash Flow |
|
89.25
+8.85%
|
81.99
|
0.00
-100.00%
|
0.23
|
| Cash Flow From Continuing Financing Activities |
|
89.25
+8.85%
|
81.99
|
0.00
-100.00%
|
0.23
|
| Net Common Stock Issuance |
|
91.08
|
0.00
|
0.00
-100.00%
|
0.23
|
| Proceeds From Stock Option Exercised |
|
0.56
+68.98%
|
0.33
|
0.00
-100.00%
|
0.23
|
| Net Other Financing Charges |
|
-2.39
+28.55%
|
-3.34
|
—
|
—
|
| Changes In Cash |
|
-14.59
-128.11%
|
51.91
+991.24%
|
-5.82
+48.54%
|
-11.32
|
| Beginning Cash Position |
|
61.64
+533.19%
|
9.73
-37.43%
|
15.56
-42.11%
|
26.88
|
| End Cash Position |
|
47.05
-23.67%
|
61.64
+533.19%
|
9.73
-37.43%
|
15.56
|
| Free Cash Flow |
|
-54.27
-198.24%
|
-18.20
-212.43%
|
-5.82
+44.76%
|
-10.54
|
| Amortization Of Securities |
|
-1.31
-1260.42%
|
-0.10
|
0.00
|
—
|
| Common Stock Issuance |
|
91.08
|
0.00
|
0.00
-100.00%
|
0.23
|
| Issuance Of Capital Stock |
|
91.08
+7.15%
|
85.00
|
0.00
-100.00%
|
0.23
|
| Net Preferred Stock Issuance |
|
0.00
-100.00%
|
85.00
|
0.00
|
—
|
| Preferred Stock Issuance |
|
0.00
-100.00%
|
85.00
|
0.00
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-24 View
- 10-K2026-03-23 View
- 8-K2026-03-23 View
- 8-K2026-02-27 View
- 8-K2026-02-12 View
- 42026-02-11 View
- 42026-02-11 View
- 42026-02-11 View
- 8-K2026-02-10 View
- 8-K2026-01-12 View
- 42025-12-12 View
- 42025-12-12 View
- 8-K2025-12-10 View
- 10-Q2025-11-13 View
- 8-K2025-11-13 View
- 8-K2025-11-06 View
- 8-K2025-11-04 View
- 42025-10-16 View
- 42025-10-16 View
- 8-K2025-10-09 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|